Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. (600436.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 117.70

From 52W high−39.86%

Volume1.68M

Market capCNY 74.67B

P/E (TTM)34.6x

P/S (TTM)8.3x

Div yield2.51%

Key dataSep 18, 2026

Open

CNY 117.70

From 52W high

−39.86%

Volume

1.68M

Market cap

CNY 74.67B

ValuationView details →

P/E (Fwd)

34.0x

EV/EBITDA

26.9x

P/E (TTM)

34.6x

RSI (14)

37.3

MomentumView details →

1D Return

−0.27%

YTD Return

−29.90%

ValuationView details →

P/E (Fwd)

34.0x

P/E (TTM)

34.6x

EV/EBITDA

26.9x

EV/Sales

8.3x

P/S (TTM)

8.3x

P/B (TTM)

5.2x

ProfitabilityView details →

Gross Margin

35.11%

Net Margin

22.12%

EBITDA Margin

30.63%

ROE (TTM)

12.51%

ROA (TTM)

10.35%

Asset Turnover

0.48x

GrowthView details →

Revenue YoY

−20.05%

EPS YoY

−36.68%

FCF YoY

−89.25%

Revenue CAGR 3Y

+1.17%

EPS CAGR 3Y

−4.42%

EBITDA YoY

—

MomentumView details →

1D Return

−0.27%

YTD Return

−29.90%

1Y Return

−40.62%

RSI (14)

37.3

vs 50D SMA

−8.85%

vs 200D SMA

−17.96%

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

5.02x

Quick Ratio

2.26x

Div Yield

2.51%

Div Rate

CNY 2.97

Div Growth 1Y

−7.20%

EarningsView details →

EPS (Actual)

CNY 0.57

EPS Surprise

−40.21%

Beats (12Q)

0/12

Next Q EPS Est

CNY 1.05

Avg Surprise (4Q)

−40.21%

Rev Surprise

−9.47%

Financials snapshotView financials →

Revenue (TTM)

8.60B

Net Income (TTM)

1.90B

Op. CF (TTM)

451.06M

Next earningsOct 19, 2026 →

Latest newsMore news →

Pien Tze Huang's liver disease drug revenue fell about 19% year-on-year to 2.348 billion yuan in the first half of 2026.17d ago

Pien Tze Huang reported second-quarter 2026 revenue of 1.832 billion yuan, down 18.12% year-on-year, and net profit attributable to shareholders of 349 million yuan, down 21.02%.17d ago

Similar companies

PharmGen Science, Inc.004720.KS GSK plcGSK SanofiSNY CSPC Pharmaceutical Group Limited01093.HK Bristol-Myers Squibb CompanyBMY Pfizer Inc.PFE Find similar companies →

Latest newsMore news →

Pien Tze Huang's liver disease drug revenue fell about 19% year-on-year to 2.348 billion yuan in the first half of 2026.17d ago Pien Tze Huang reported second-quarter 2026 revenue of 1.832 billion yuan, down 18.12% year-on-year, and net profit attributable to shareholders of 349 million yuan, down 21.02%.17d ago Pien Tze Huang proposed a cash dividend of 10.7 yuan per 10 shares, totaling 646 million yuan.23d ago